Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) has emerged as a notable player in the biopharmaceutical sector, transitioning from a development-stage company to one with commercial revenue. The company's FDA-approved immunotherapy, LYMPHIR (denileukin diftitox-cxdl), launched commercially in December 2025, generated $5.6 million in net revenue during the first six months of fiscal 2026, with gross margins of approximately 80%. This milestone provides Citius with a revenue-generating asset in the oncology market, offering a foundation for future growth.
The approval of LYMPHIR for relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) marks a significant achievement, as it addresses a rare form of non-Hodgkin lymphoma with limited treatment options. Beyond this indication, Citius is exploring the drug's potential in combination with other therapies, including pembrolizumab for gynecologic cancers and prior to CAR-T therapy for diffuse large B-cell lymphoma. Positive topline results from both Phase 1 studies were reported in fiscal 2026, indicating possible expansion of LYMPHIR's use and market potential.
In addition to its commercial product, Citius boasts a diversified late-stage pipeline targeting critical-care indications with significant unmet needs. Mino-Lok, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs), met its primary and secondary endpoints in a pivotal Phase 3 trial. This therapy is particularly important because there are currently no FDA-approved treatments specifically indicated to salvage infected central venous catheters, and catheter removal and reinsertion carry risks such as pneumothorax and arterial puncture. Mino-Lok has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA, and the company has received guidance supporting a potential New Drug Application submission. The worldwide sales potential for Mino-Lok is estimated at approximately $1.8 billion, underscoring its commercial significance.
Another promising candidate is Halo-Lido (CITI-002), a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. With an estimated 10 million people in the U.S. reporting hemorrhoid symptoms annually, and no FDA-approved prescription products currently available for this condition, Halo-Lido could become the first of its kind if approved. The company completed a Phase 2b study in 2023 and has met with the FDA to discuss next steps, positioning this program as a potential near-term catalyst.
Citius is also advancing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for the treatment of acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. Interim results from a proof-of-concept sheep model showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls, warranting further studies. This program adds another layer of diversification to the company's portfolio.
The strategic combination of a commercial product and multiple clinical-stage assets provides Citius with several paths for future development and value creation. The company's experienced leadership team, including CEO Leonard Mazur and Executive Vice Chairman Myron Holubiak, brings decades of pharmaceutical development, commercialization, and sales expertise. With LYMPHIR now generating revenue and other programs progressing, Citius is positioned to capitalize on its diversified portfolio and address critical medical needs.
For more information about Citius Pharmaceuticals, visit https://www.citiuspharma.com/.
